

The Environment and IBD

Charles N. Bernstein, MD

University of Manitoba

IBD Clinical and Research Centre

Winnipeg, Manitoba, Canada



BC


AB

SK


MB

NS

Age-specific incidence of Crohn's Disease: by Province



Age-specific prevalence of Crohn's Disease: by Province (2000)



Projected prevalence of IBD in Canada in 2000

Population = 30,750,087

Prevalence of Crohn's disease: 85,854


Prevalence of UC: 64,975

Total IBD: 150,829


?2008: 180,000

- **MB rates similar to elsewhere in Canada**
- **Low rates of Crohn's disease in BC;
22% visible minorities**
- **High rates of both Crohn's & UC in
Canada;
*?North-South gradient***


European IBD epidemiology data from 1991-1993




European IBD epidemiology data from 1991-1993



Incidence Rate of Crohn's Disease-Adults




Incidence rates of Ulcerative Colitis -Adults




Bernstein Shanahan Gut 2008


Comparison of Adults with IBD




Comparison of Children with IBD



Annual Age-Adjusted Prevalence of CD and UC, by First Nation (FN) Status, Manitoba.



Pathogenesis of IBD



Genes

- **Family history**
- **Twin studies**
- **NOD-2**

The evidence for environment from family/gene studies

- **Monozygotic twins-**
<50% concordance for CD
<10% concordance for UC

Population based study in Manitoba

NOD-2 mutations (1 or 2):

14% healthy controls (168,000 Manitobans without CD with NOD-2 mutations)

37% CD (1295 Manitobans with CD & NOD-2 mutations)


Pathogenesis of Crohn's Disease

CARD15/NOD2 variants



Genetic
Susceptibility

Environment
(+microflora)

Host
(immune)
Response



**Inverse relation between
the incidence of prototypical infectious diseases (A) and
the incidence of immune disorders (B)
from 1950 to 2000**



Mechanisms of disease: the hygiene hypothesis revisited.

Guarner F Nat Clin Pract Gastroenterol Hepatol 2006

SIMON & GARFUNKEL
OLD FRIENDS




LIVE ON STAGE



Helminths, saprophytic mycobacteria, bifidobacteria, lactobacilli

Rook and Lowery Trends Immunol 2008



Old friend	Site of inflammation	Animal
<i>Mycobacterium vaccae</i>	Airway	Mice
<i>Mycobacterium vaccae</i>	Skin	Dogs
<i>Heligmosomoides polygyrus</i>	Airway	Mice
<i>Schistosoma mansoni</i>	DM I	NOD mice
<i>Trichuris suis</i>	CD	Humans

Features of lifestyle in developed countries

- Improved sanitation
- Decline in endemic parasitism
- Life on concrete (less exposure to soil microbes)
- Decline in *H pylori* and other communicable infections
- Increased antibiotic usage
- Vaccination
- Smaller family size
- Less crowded living conditions
- Refrigeration
- Delayed exposure to mucosal infections
- Sedentary lifestyle and obesity
- Reduced consumption of fermented food products
- Increased consumption of refined sugars and saturated fats

	Bernstein <i>Am J GI 06</i>	Amre <i>Am J GI 06</i>	Baron <i>Gut 05</i>
Study type	Pop-based	Clinic	Pop-based
Age	18-50	<17	<20
Location	Manitoba	Fr Can. PQ	N France
CD (n)	364	222	194
1st Gen Canadian	0.3 (0.2-0.6)	-	
Farm living	0.6 (0.5-0.9)	-	-

Bernstein

Am J GI 06

Amre

Am J GI 06

Baron

Gut 05

**Passive
smoking**

1.03
(1.01-1.04)

NS

NS

**Personal
towel**

-

0.5
(0.2-0.9)

-

**More
crowding**

0.9
(0.8-0.96)

-

-

**Less
crowding**

-

0.3
(0.1-0.8)

-

**Bedroom
sharing**

-

-

1.6
(1.0-2.4)

Bernstein

Am J GI 06

Amre

Am J GI 06

Baron

Gut 05

**Daycare <6
mos**

-

4.5

(1.4-13.7)

-

Pets

<5 y; cat

NS

2.0

0.7 (0.5-0.96)

(0.9-4.5)

**Breast
feeding**

NE

NS

1.6

(1.1-2.4)

**Type of
water**

**tap-
suggestive**

NS

0.5

(0.3-0.8)

**MMR
vaccine**

NE

NS

0.5

(0.35-0.9)

Bernstein

Am J GI 06

Amre

Am J GI 06

Baron

Gut 05

**“Hygiene
Hypothesis”**

Supported

Refuted

Refuted

Pursuing exogenous microbes

	Crohn's n=24	UC n=28	Controls n=28 (9 sibs)
M. paratuberculosis	0	1	6
Type-2 circovirus	0	0	0
Brachyspira pilosicoli	0	0	0
Brachyspira hyodysenteriae	0	0	0
Coxiella burnetti	0	0	0
Chlamydia psittaci	0	0	0
Bovine viral diarrhea	0	0	0

Reconciling MAP and IBD epi

**Mod to high
MAP in cattle**

**Low MAP in
cattle**

**US, Canada,
Denmark**



High IBD



**Sweden,
Norway**

Chile



Low IBD

Map serology (Michael Collins, Univ Wisconsin)

Crohn's disease n=297	+ve 39%
Ulcerative colitis n=136	30%
Sib controls n=143	36%
Controls n=407	34%

Does *M. paratuberculosis* cause Crohn's?


- **Viability of the organism is difficult to find in human tissue**
- **Positive and negative studies using PCR in tissue**
- **Antibiotic studies with agents that could treat MAP do not cure Crohn's**
- **An immunodiagnostic test to prove MAP infections in humans is lacking**

Does *M. paratuberculosis* cause Crohn's?

- ?
- **But no convincing evidence yet**
- **?permissive role**

Gut Flora as an Asset

- Bacterial antagonism
- Primes mucosal immunity
- Maintenance of peristalsis
- Maintenance of mucosal integrity
- Metabolism of dietary carcinogens
- Synthesis of vits. K & B complex
- Metabolism of prodrugs




Human distal gut microbiome contains

>100X as many genes as our

2.85 billion bp human genome

Post operative relapse of Crohn's disease




The enemy is within the faecal stream

**Characterization of the
Intestinal Microflora in
Inflammatory Bowel
Disease Using Molecular
Methods**



***University of Manitoba +
Stanford University collaboration***

Bacterial phyla represented in the healthy human gut



**Bacterial 16S rDNA sequences
(n=11831)**

**Archaeal 16S rDNA sequences
(n=1524)**

**Phylogenetic analysis using 99% minimum similarity
as a threshold for any pair of sequences in a phylotype**

**Bacterial phylotypes
(n=395)**

**Archaeal phylotypes (n=1)
(*methanobrevibacter smithii*)**

*** 240 (61%) = novel (not in public databases)
* 80% from species that are not cultivated**

*** Most= *Firmicutes* & *Bacteroidetes*
* Relatively few sequences of *Proteobacteria*, *Actinobacteria*,
Fusobacteria, *Verrucomicrobia***

Conclusions of broad sequence PCR in CD, UC, HC


- This preliminary comparative 16S rDNA analysis reveals differences in the composition and diversity of the colonic mucosal microbiota in CD, UC, and HC.
- IBD bacterial microbiota = less diverse than controls
- CD microbiota = less diverse than UC or controls
- CD microbiota = lack of *Bacteroidetes* & *Firmicutes* predominance of *Proteobacteria* sequences (especially *E. coli* and *Pseudomonas* spp.).
- Inter-subject differences are the greatest sources of variability between libraries.

**Molecular analysis of IBD tissues
at the University of Manitoba**

For phylogenetic studies

the following PCR-based methods were used (Krause lab):


Ribosomal intergenic spacer analysis PCR (RISA-PCR) for amplification of intergenic transcribed spacers between the 16S and 23S rDNA;



Indices of species richness


	Control	CD	UC
Cecum	81	83	99
Rectum	64	51	99
Total	86	95	92

Identification of unique DNA fragments from tissue samples of IBD patients using RISA-PCR



→ Indicates position (size) of unique bands present in samples from patients
controls

N1, N2 – negative controls




A hypothesis

- **The genetic predisposition to have impaired defense against flora bacteria (?upregulation of CEACAM on enterocytes)**
- **An E coli species increased in IBD tissue (more easily found in uninflamed tissue)**
- **The E coli makes proteases in increased quantities and diversities that the host can not defend against**
- **There is mucosal damage and the immune cascade is initiated**



Ability of mannan to inhibit mucosal phagocyte function

Mpofu Gastroenterology 2007




A. Presence of *S cerevisiae* mannans inhibits monocyte killing of CD assoc. *E coli*

B. CD assoc *E coli* survives even better than ATCC *E coli*



Map culture supernatant increased survival of CD assoc E coli in monocytes

F. prausnitzii proportions in the ileal MAM using FISH at the time of surgery and at 6 months according to the endoscopic recurrence status. *, P = 0.03.




Sokol H. et.al. PNAS 2008;105:16731-16736


UC Prevalence, 2001, Smoothed Rates

Cases/10,000, Age Standardized to the 1996 Manitoba Population
Smoothing - Mean Nearest Neighbor(10,000)

Hot and cold spots in the province



City of Winnipeg



Diet and IBD

Is this the link?

Newly dx pediatric CD

Diet case-control study

Amre Am J Gastroenterol 2006

Fish	OR=0.46 (0.2-1.06)
Fruits	0.37 (0.16-0.86)
Nuts	0.16 (0.04-0.58)
Dietary fiber	0.12 (0.04-0.37)
LC ω-3 FA	0.44 (0.19-1.00)
Sugars	No assoc

Sugar

- **Impact on gut flora**
- **Source of mannans**

Associations between CD & sugar consumption

Riordan Eur J Clin Nutr 1998

- **No definite relationship could be identified**
- **No relationship between national sugar consumption and CD incidence (epi studies)**
- **CD = greater consumption of sugar vs controls BUT**

- **Duration of disease influences recall**
- **Incomplete recollection of the types of foods eaten and imprecise estimation of portion size**
- **Estimates of error overlooked since clinical differences between cases and controls are small**
- **Prediagnosis symptoms may affect intake pre diagnosis; rarely ask for presymptom diet.**
- **Patient awareness of study aim may lead to under or over reporting**
- **Ability to separate retrospectively present eating patterns from those in distant past**

Current sugar intake during disease

- **?consequence of active disease**
- **?consequence of Rx (decreasing appetite)**
- **?consequence of past dietary advice**


Ecological study of diet in Japan

Shoda Am J Clin Nutr '96

**Multivariate model; correlating
with CD incidence:**

- **Animal protein intake**
- **ω 6 fatty acids/ ω 3 fatty acids**

Fish oil





The NEW ENGLAND
JOURNAL of MEDICINE

Beluzzi et al. June 13, 1996 Volume 334:1557-1560

Effect of an Enteric-Coated Fish-Oil Preparation on Relapses in Crohn's Disease

**Omega-3 free fatty acids for the maintenance of
remission in Crohn disease:
the EPIC Randomized Controlled Trials**

Feagan et al. JAMA 2008 Apr 9; 299(14):1690-7

- **EPIC-1**
in chronic remission (n=375)
- **EPIC-2**
post steroid induced remission (n=379)

RESULTS: The rate of relapse at 1 year:

- **EPIC-1 fish oil- 31.6% placebo-35.7% (p = 0.30).**
- **EPIC-2 fish oil- 47.8% placebo-48.8% (p = 0.48).**

- **CONCLUSION:** Treatment with omega-3 free fatty acids was not effective for the prevention of relapse in Crohn disease.

The fish oil of 2008

VITAMIN D

Vitamin D deficiency in IBD

- 25-OH vit D <35 nmol/L

18% CD (n=84)

17% UC (n=42)

- 25-OH vit D <75 nmol/L

70% CD

79% UC

Daily Calcium and Vitamin D Intake by IBD Patients

Study	IBD	Control	Country
Bernstein	743	–	US
Reed	825	–	US
Silvennoinen	1034	1334	Finland
Bernstein	667	–	Canada

Vitamin D

Bernstein	128 IU	–	US
Reed	212 IU	–	US
Vogelsang	40 IU	44 IU	Austria
Bernstein	146 IU	–	Canada

**% consuming inadequate intake
of vitamin D
($<66\%$ of recommended)**

38% CD


32% UC

Risk for vitamin D deficiency ($<$ less than 75 nmol/L): Multivariate analysis

controlling for sex, IBD type, IBD status, ileum involvement, medication use, surgical history, duration of disease, use of vitamin/mineral supplementation, serum vitamin B6, B12, carotene, ferritin and zinc.

**Vitamin D deficiency higher in UC
(OR, 3.40; 95% CI 0.86-13.5).**

The endocrine, paracrine and intracrine functions of vitamin D



**Tobacco is the most consistent
environmental risk factor identified**

**Tobacco use increases risk for
Crohn's disease 2-4x**

+ve correlation smoking and Crohn's incidence

Vessey, Br Med J (Clin Res Ed) 1986

Tobin Gastroenterology 1987

Benoni C Scand J Gastroenterol 1987

Lindberg E, Gut 1988

Katschinski B, Gut 1988

Logan RF, Int J Epidemiol 1989

Lashner BA, Gastroenterology 1989

Sandler RS, Epidemiology 1992

Corrao G, Int J Epidemiol 1998

- **+ve correlation between perinatal or childhood passive smoke exposure and Crohn's incidence**

Persson, Gut 1990

Lashner, Am J Gastroenterol 1993

Bernstein, Am J Gastroenterol 2006

- **+ve correlation for smoking and more active Crohn's disease**

Russel MG, Inflamm Bowel Dis 1998

- **+ve correlation for smoking and ileal rather than colonic Crohn's disease**

Lindberg E, Gut 1992

Russel MG, Inflamm Bowel Dis 1998

- **Smokers have higher relapse rates after medically induced remissions**

Duffy LC, Am J Prev Med 1990.

Timmer A, Gastroenterology 1998.

Cosnes J, Aliment Pharmacol Ther 1999.

- **Smokers have higher relapse rates after surgically induced remissions**

Sutherland LR, Gastroenterology 1990.

Cottone M, Gastroenterology 1994.

Breuer-Katschinski BD, Eur J Gastroenterol Hepatol 1996.

Moskovitz D, Int J Colorectal Dis 1999.

•Quitters have lower relapse rates than those who continue to smoke

Cosnes J, Gastroenterology 2001.

Environmental-gene interaction

- Higher relapse rate among smokers post surgical induced remission is more common among females

Yamamoto T, Br J Surg 2000.


- Smoking accounts for the discordance between monozygous twins for Crohn's disease incidence in a Danish study

Orholm M, Scand J Gastroenterol 2000.

- Patients with familial Crohn's disease were more likely to be smokers than sporadic non familial Crohn's disease


Brignola C, Am J Gastroenterol 2000

Smoking History Among Crohn's Disease (CD) and Ulcerative Colitis (UC) Patients, by Gender



www.nationmaster.com/graph/hea_tob_adu_mal_smo-health-tobacco-adult-male-smokers

Adult male smokers



The Passover Seder and 4 sons



Wicked son



Wise son



Simple son



**The one who does not know
how to ask the question**

"ASSESSING ENVIRONMENTAL RISK FACTORS AFFECTING THE INFLAMMATORY BOWEL DISEASES"


- A joint symposium of CCFC-CCFA May '07**
- Toronto, Ontario**
- Proceedings in Inflamm Bowel Dis 2008;14:1139.**

DAISY


Diabetes Autoimmune Study in the Young

- **Having sibling or parent with DMI or Celiac**
- **Having high risk HLA type**
- **Diet collection at 3,6,9,12,15 mos**
- **1307 kids enrolled at birth-311 FHX of DMI**
- **996 picked up at newborn HLA screening**
- **Exposures to gluten 100% by 12 mos,**
- **Initial +ve TTG=2 yrs (mean age at conversion= 4.7 yrs)**

Entire Cohort



Children With Positive HLA-DR3



No. at Risk

Month of Exposure

1-3	43	43	40	33	30	21	15	13	8	6
4-6	586	567	472	375	319	253	200	153	110	61
≥7	931	905	765	618	528	431	358	289	188	105

1-3	14	14	13	10	9	5	3	2		
4-6	311	297	257	205	175	137	104	73	46	20
≥7	452	439	377	302	258	208	165	123	77	40

Hazard rate of developing CDA by timing of food introduction

Timing of food intro	0-3 Mos	4-6 mos	≥7 mos
Wheats, barley, rye	5.17 (1.44-18.57)	1.00	1.87 (0.97-3.6)
Rice	0.86 (0.4-1.86)	1.00	1.25 (0.58-2.69)

- **Similar outcome for development of islet cell Abs and DMI**
- **No protective effect of breastfeeding**

Summary

Or where do we go from here?

- **Developing world and new IBD “markets”**
- **Epidemiology in migrant populations**
- **Pediatric IBD**